1. Bollerslev J, Henriksen K, Nielsen MF, Brixen K, Van Hul W. Autosomal dominant osteopetrosis revisited: lessons from recent studies. Eur J Endocrinol 2013;169:R39-R57.
[CROSSREF] [PUBMED]
3. Coudert AE, de Vernejoul MC, Muraca M, Del Fattore A. Osteopetrosis and its relevance for the discovery of new functions associated with the skeleton. Int J Endocrinol 2015;2015:372156.
[CROSSREF] [PUBMED] [PMC] [PDF]
4. Benichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients. Bone 2000;26:87-93.
[CROSSREF] [PUBMED]
5. Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 2006;43:315-325.
[CROSSREF] [PUBMED]
6. Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005;24:1079-1091.
[CROSSREF] [PUBMED] [PMC]
7. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002;30:3894-3900.
[CROSSREF] [PUBMED] [PMC] [PDF]
8. Senel K, Ugur M, Erdal A, Ozdemir H. Type II autosomal dominant osteopetrosis. Rheumatol Int 2002;22:116-118.
[CROSSREF] [PUBMED] [PDF]
9. Waguespack SG, Hui SL, Dimeglio LA, Econs MJ. Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab 2007;92:771-778.
[CROSSREF] [PUBMED] [PDF]
10. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000;113(Pt 3):377-381.
[PUBMED]
11. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001;104:205-215.
[CROSSREF] [PUBMED]
12. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001;10:2861-2867.
[CROSSREF] [PUBMED] [PDF]
13. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144-1153.
[CROSSREF]
14. Mullard A. Merck &Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discov 2016;15:669.
[PMC]
15. Benichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC, Van Hul W. Mapping of autosomal dominant osteopetrosis type II (Albers-Schonberg disease) to chromosome 16p13.3. Am J Hum Genet 2001;69:647-654.
[CROSSREF] [PUBMED] [PMC]
16. Pang Q, Chi Y, Zhao Z, Xing X, Li M, Wang O, et al. Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients. Osteoporos Int 2016;27:1047-1055.
[CROSSREF] [PDF]
17. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424.
[CROSSREF] [PUBMED] [PMC] [PDF]
18. Sui W, Ou M, Liang J, Ding M, Chen J, Liu W, et al. Rapid gene identification in a Chinese osteopetrosis family by whole exome sequencing. Gene 2013;516:311-315.
[CROSSREF] [PUBMED]
19. Zheng H, Shao C, Zheng Y, He JW, Fu WZ, Wang C, et al. Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab 2016;34:440-446.
[CROSSREF] [PUBMED] [PDF]